Autonomic Dysfunction Targeting Therapy is a novel therapeutic approach specifically designed to address the profound autonomic failure that characterizes Multiple System Atrophy (MSA). Unlike Parkinson's disease, MSA produces severe and often treatment-resistant autonomic dysfunction including neurogenic orthostatic hypotension, urinary dysfunction, gastroparesis, and erectile dysfunction, contributing significantly to disability and reduced quality of life.
MSA is classified as an α-synucleinopathy with predominant autonomic involvement. The autonomic dysfunction in MSA results from degeneration of peripheral autonomic neurons (postganglionic sympathetic neurons) and central autonomic nuclei, including the ventrolateral medulla, nucleus tractus solitarius, and intermediolateral cell column.[@palma2022]
Core autonomic manifestations:
- Neurogenic orthostatic hypotension (nOH) — Severe drop in blood pressure upon standing due to impaired sympathetic vasoconstriction
- Urinary dysfunction — Overactive bladder (urgency, frequency) progressing to incomplete retention
- Gastrointestinal dysmotility — Gastroparesis, constipation, dysphagia
- Erectile dysfunction — Often an early presenting symptom in men
- Sudomotor dysfunction — Anhidrosis or hyperhidrosis patterns
- Reflex bradycardia — Impaired baroreflex-mediated heart rate responses
This therapy employs multiple complementary mechanisms:
- Norepinephrine restoration — Midodrine, droxidopa, and atomoxetine to enhance sympathetic tone
- Baroreflex amplification — Novel devices and pharmacologic agents to enhance baroreceptor sensitivity
- Peripheral autonomic modulation — Targeting postganglionic sympathetic nerve function
- Bladder/GI motility agents — Muscarinic antagonists for overactive bladder, prokinetics for GI dysmotility
- Central autonomic network modulation — Targeting brainstem autonomic nuclei
| Dimension |
Score |
Rationale |
| Novelty |
6 |
Builds on established autonomic pharmacotherapy with novel delivery and combinatorial approaches |
| Mechanistic Rationale |
9 |
Strong evidence for autonomic dysfunction as a core MSA feature with well-characterized pathophysiology |
| Root-Cause Coverage |
5 |
Addresses symptomatic management, not the underlying α-synuclein pathology |
| Delivery Feasibility |
8 |
All agents are orally bioavailable; device approaches have established delivery pathways |
| Safety Plausibility |
7 |
Established safety profiles but requires careful monitoring for supine hypertension and cardiovascular effects |
| Combinability |
8 |
Highly synergistic with α-synuclein targeting, neuroprotection, and symptomatic therapies |
| Biomarker Availability |
8 |
Tilt-table testing, ambulatory blood pressure monitoring, bladder function studies readily available |
| De-risking Path |
8 |
Can leverage existing drug safety profiles and regulatory pathways for each component |
| Multi-disease Potential |
7 |
Applicable to pure autonomic failure, PD with autonomic dysfunction, diabetic autonomic neuropathy |
| Patient Impact |
9 |
Addresses severe disability and high unmet need; improves quality of life significantly |
Total Score: 72/100
| Disease |
Coverage Score |
Rationale |
| Alzheimer's Disease |
3 |
May have mild autonomic involvement in later stages |
| Parkinson's Disease |
7 |
Autonomic dysfunction common in PD, especially in advanced stages |
| ALS |
4 |
Autonomic involvement in later stages, particularly cardiac autonomic dysfunction |
| FTD |
3 |
Variable autonomic involvement depending on subtype |
| PSP |
6 |
Autonomic dysfunction present but less prominent than MSA |
| MSA |
10 |
Primary indication; core feature of the disease |
| Aging |
5 |
Age-related autonomic decline may benefit from this approach |
- Characterize autonomic dysfunction subtypes in MSA patient cohorts
- Identify biomarker predictors of treatment response
- Evaluate novel agent combinations in appropriate animal models
- Supine hypertension: Careful dosing timing and bedtime blood pressure management
- Urinary retention: Monitor post-void residuals, especially in males
- Cardiac arrhythmias: ECG monitoring with some agents
Autonomic Dysfunction Targeting Therapy is highly synergistic with:
- + α-Synuclein Aggregation Inhibition — Address root cause while managing symptoms
- + Neuroprotective strategies — Protect remaining autonomic neurons
- + Cerebellar Circuit Protection — Address combined MSA-C autonomic symptoms
- + Physical countermeasures — Compression garments, hydration, positional strategies
- + MSA Combination Therapy — Integrated multi-target approach
- Droxidopa (Northera) FDA-approved for nOH with grade B recommendation[@biaggioni2014]
- Midodrine widely used for nOH with established efficacy[@low1997]
- Atomoxetine shown to improve standing BP in central autonomic failure[@okamoto2015]
- Botulinum toxin injections for severe overactive bladder[@kulaksizoglu2013]
- Postganglionic sympathetic neuronal loss documented in MSA autonomic failure[@kaufmann2013]
- Cardiac MIBG uptake reduced in MSA versus PD, indicating sympathetic denervation[@takatsu2003]
- MRI shows degeneration of brainstem autonomic nuclei in MSA[@cilia2021]
- Plasma norepinephrine levels correlate with orthostatic hypotension severity
- Bladder dysfunction severity correlates with disease progression
- Heart rate variability measures predict autonomic dysfunction severity
- Characterize MSA patient subtypes based on autonomic dysfunction pattern
- Optimize combination regimens based on pharmacokinetic interactions
- Establish biomarker endpoints for each autonomic domain
- First-in-human studies of novel agents with enhanced brainstem penetration
- Develop personalized medicine approach based on autonomic subtype
- Initiate combination therapy trials
- Pivotal registration trials for lead combinations
- Develop device-based approaches for refractory cases
- Expand to other α-synucleinopathies with autonomic dysfunction
- Identify lead compounds: Prioritize agents with central nervous system penetration
- Biomarker development: Standardize autonomic function testing protocols
- Clinical trial design: Leverage existing nOH trial infrastructure
- Patient stratification: Develop autonomic phenotype classification for MSA
- Regulatory pathway: Pursue orphan drug designation for MSA-specific indication
The parkinsonian variant of MSA (MSA-P) typically presents with:
- Cardiovascular autonomic failure: Severe orthostatic hypotension due to sympathetic denervation
- Urinary dysfunction: Early onset overactive bladder symptoms, typically within 2 years of motor symptoms
- Gastrointestinal involvement: Gastroparesis and constipation are prominent
- Thermal dysregulation: Anhidrosis or hyperhidrosis episodes
The autonomic phenotype in MSA-P correlates with putaminal dopaminergic denervation and may show less severe baroreflex impairment compared to MSA-C.
The cerebellar variant (MSA-C) often demonstrates:
- Cardiovascular involvement: Orthostatic hypotension, though sometimes less severe than MSA-P
- Genitourinary symptoms: Similar to MSA-P but may develop later
- Gastrointestinal dysmotility: Prominent dysphagia and constipation
- Sleep disorders: REM sleep behavior disorder is common
The MSA-C autonomic phenotype often parallels the severity of cerebellar involvement and brainstem pathology.
A proposed staging system for MSA autonomic dysfunction:
- Stage 1 (Mild): Isolated orthostatic hypotension or urinary symptoms, preserved baroreflex
- Stage 2 (Moderate): Multiple autonomic domains affected, mild baroreflex impairment
- Stage 3 (Severe): Progressive autonomic failure, significant baroreflex failure
- Stage 4 (End-stage): Complete autonomic failure, severe supine hypertension complications
Midodrine is a prodrug that is converted to the active metabolite desglymidodrine, which acts as a direct alpha-1 adrenergic receptor agonist. The pharmacologic profile includes:
- Mechanism: Vasoconstriction through alpha-1 receptor activation
- Dosing: 2.5-10 mg three times daily, with last dose before 6 PM to minimize supine hypertension
- Duration: Onset 1 hour, duration 2-3 hours
- Side effects: Supine hypertension, scalp pruritus, urinary retention
- Contraindications: Severe hypertension, urinary retention, pheochromocytoma
The therapeutic effect of midodrine in MSA is limited by the degree of sympathetic denervation—patients with complete postganglionic sympathetic failure respond poorly.
Droxidopa (L-DOPS) is a synthetic amino acid converted to norepinephrine by dopa-decarboxylase:
- Mechanism: Direct norepinephrine prodrug, restores sympathetic tone
- Dosing: 100-600 mg three times daily
- Duration: Onset 1-2 hours, duration 4-6 hours
- Side effects: Supine hypertension, headache, nausea
- Advantage: Can cross the blood-brain barrier and restore central norepinephrine
Droxidopa showed significant benefit over placebo in the pivotal clinical trials for neurogenic orthostatic hypotension, with improvements in dizziness, lightheadedness, and composite autonomic symptom scores.
Atomoxetine is a selective norepinephrine reuptake inhibitor:
- Mechanism: Increases synaptic norepinephrine by blocking the norepinephrine transporter
- Dosing: 10-18 mg twice daily
- Onset: 2-4 hours
- Unique benefit: May improve central sympathetic outflow in addition to peripheral effects
- Side effects: Insomnia, decreased appetite, dry mouth
Atomoxetine has shown particular benefit in central autonomic failure conditions like MSA, where it can enhance sympathetic outflow through central mechanisms.
¶ Lower Body Compression
External compression devices represent a non-pharmacological approach to managing orthostatic hypotension:
- Abdominal compression: Reduces venous pooling in splanchnic circulation
- Full leg compression: Graduated compression stockings (30-40 mmHg)
- Portable devices: Self-contained compression units for ambulation
The efficacy of compression therapy depends on patient mobility and compliance. Studies show 15-30 mmHg improvement in systolic blood pressure with adequate compression.
For patients with refractory bradycardia:
- Dual-chamber pacing: Maintains adequate heart rate during posture changes
- Baroreflex activation: Emerging technology for severe autonomic failure
- Indications: Significant bradycardia limiting physical therapy participation
- Splanchnic denervation: Radiofrequency ablation of splanchnic nerves under investigation
- Closed-loop systems: Automated blood pressure regulation using sensor feedback
- Implantable compression: Device-based abdominal compression systems
Autonomic dysfunction in MSA contributes significantly to disability:
- Mobility limitation: Orthostatic hypotension causes dizziness and pre-syncope with standing
- ** Falls**: Orthostatic hypotension accounts for 20-30% of falls in MSA
- Social isolation: Fear of public episodes limits social participation
- Sleep disruption: Nocturia and RBD fragment sleep architecture
- Structured hydration protocol: 2-3 liters daily with adequate salt intake
- Head-of-bed elevation: 30-degree elevation reduces nocturnal diuresis
- Physical counter-maneuvers: Leg crossing, muscle pumping during pre-syncope
- Environmental modifications: Cool environment, avoid heat exposure
Regular assessment should include:
- Supine and standing blood pressure: Monitored at each visit
- Heart rate response: 30:30 ratio and 30:15 ratio for baroreflex assessment
- Bladder diary: Frequency, volume, nocturia episodes
- Bowel habit diary: Stool frequency, consistency
- Weight monitoring: Detect catabolism and nutritional decline
- Plasma norepinephrine: Correlates with sympathetic function
- Heart rate variability: Reduced HRV predicts autonomic decline
- Skin biopsy: Phosphorylated α-syn in autonomic nerve fibers
- Composite Autonomic Scoring Scale (CASS): Quantitative autonomic assessment
- Wenning GK, Stankovic I, Vignatelli L, et al, The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (2022)
- Palma JA, Kaufmann H, Treatment of autonomic dysfunction in Parkinson disease and multiple system atrophy (2022)
- Biaggioni I, Okamoto LE,输麻 J, et al, Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial (2014)
- Low PA, Gilden JL, Freeman R, et al, Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension (1997)
- Okamoto LE, Shibao C, Gamboa A, et al, Atomoxetine increases standing blood pressure in autonomic failure (2015)
- Kulaksizoglu H, Bebek N, Sen A, et al, OnabotulinumtoxinA for neurogenic overactive bladder in patients with multiple system atrophy (2013)
- Kaufmann H, Goldstein DS, Autonomic dysfunction in multiple system atrophy (2013)
- Takatsu H, Nishida H, Matsui H, et al, Cardiac sympathetic denervation in multiple system atrophy and Parkinson's disease (2003)
- Cilia R, Maruca E, Buffa LM, et al, Neuroimaging of autonomic dysfunction in multiple system atrophy (2021)
- Gibbons CH, Simon DK, Altomare M, et al, Failure of splanchnic vasoconstriction in multiple system atrophy (2017)
- Sandroni P, Low PA, Ferrer TP, et al, Thermal pain somatosensory threshold in autonomic failure (1995)
- Freeman R, Syncope in multiple system atrophy (1999)
- Low PA, Tomalia VA, Orthostatic hypotension: mechanisms, causes, management (2015)
- Chelimsky G, Chelimsky T, Non-motor features of autonomic dysfunction in Parkinson's disease and multiple system atrophy (2019)
- Suzuki M, Uchiyama M, Shinoda M, et al, Sleep disturbances in multiple system atrophy (2019)
- Jost WH, Gastrointestinal dysfunction in multiple system atrophy (2003)
- Singer W, Sandroni P, Opfer-Gehrking TL, et al, Pyridostigmine treatment trial in neurogenic orthostatic hypotension (2006)
- Ketch T, Biaggioni I, New pharmacologic approaches to orthostatic hypotension (2019)
- Ramalho J, Castillo C, Narayana P, et al, Atomoxetine for treatment of orthostatic hypotension (2020)